Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Chases Another Synthetic Stimulant Off Supplement Ingredient Menu

This article was originally published in The Tan Sheet

Executive Summary

CFSAN tells 14 firms the stimulant DMBA – identified by names including 1,3-dimethylbutylamine, 2-amino-4-methylpentane, AMP citrate and 4-methyl-2-pentanamine – has “no history of use or other evidence of safety … when used as a dietary ingredient.”

You may also be interested in...



Kirkman Acquires Rose, IQ Recalls Picamilon Supplement: Health And Wellness Industry News Roundup

Recalls reported by FDA for health and wellness products.

Hi-Tech Lawsuit Calls FDA DMAA Enforcement “Bullying Tactics”

Hi-Tech Pharmaceuticals files a lawsuit in federal court after receiving an administrative detention order from FDA to stop distributing its DMAA-containing products. The firm argues FDA should conduct a rulemaking to propose banning DMAA rather than ordering firms to stop using it.

Australian Teeth Whitener Marketer Frowns On Industry Self-Regulation Referencing US Laws

HiSmile appeals NAD recommendation following review on P&G challenge to discontinue ad claims on its website and in social media videos stating peroxide-containing whitening products are “painful” or cause pain, break down and impact gums and teeth, or “damage” gums.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS107645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel